Previous Close | 1.4000 |
Open | 1.4000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 134.00 |
Expire Date | 2024-06-14 |
Day's Range | 1.4000 - 1.4000 |
Contract Range | N/A |
Volume | |
Open Interest | 19 |
The FDA approved Moderna's RSV vaccine, allowing the biotech to launch its second-ever product. But Moderna stock retreated.
mRESVIA is Moderna's second approved product and the only RSV vaccine available in single-dose pre-filled syringes CAMBRIDGE, MA / ACCESSWIRE / May 31, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the U.S. Food and Drug Administration (FDA) ...
Moderna stock is on the rise again as investors focus on the potential need for a bird flu vaccine. Is MRNA stock a buy right now?